Immuno-Oncology Assay Market Outlook and Insigh

Comments · 60 Views

The immuno-oncology assay market is anticipated to reach US$ 18.1 billion in 2034

The immuno-oncology assay market is anticipated to reach US$ 18.1 billion in 2034, from an estimated US$ 5.6 billion in 2024. The industry is projected to grow at a CAGR of 12.4% between 2024 and 2034.

https://www.globenewswire.com/en/news-release/2024/03/06/2841523/0/en/Global-Immuno-Oncology-Assay-Market-is-Expected-to-Reach-US-18-1-Billion-Anticipated-CAGR-from-2024-to-2034-is-12-4-Future-Market-Insights-Inc.html

The increasing adoption of immunotherapy in cancer treatment is driving the demand for immuno-oncology assays. These assays are crucial for assessing the efficacy of immunotherapeutic agents, predicting patient responses, and monitoring treatment outcomes.

There is a growing emphasis on biomarker-driven approaches in cancer care, leading to the discovery of novel biomarkers associated with immunotherapy response. Immuno-oncology assays play a critical role in identifying predictive and prognostic biomarkers, and facilitating personalized treatment strategies.

Burgeoning investments in immuno-oncology research and clinical trials is driving market growth. Pharmaceutical companies, biotechnology firms, and academic institutions are conducting extensive research to develop novel immunotherapies and validate immuno-oncology assays in clinical settings.

Favorable regulatory frameworks and reimbursement policies for immuno-oncology assays are facilitating market growth. Regulatory approvals and reimbursement coverage increase the adoption of immuno-oncology assays in clinical practice, driving market expansion.

Key Takeaways from the Market Study:

From 2019 to 2023, the immuno-oncology assay market expanded at a CAGR of 15.4%.
Based on technology, the Checkpoint Inhibitors segment is expected to rise at a CAGR of 11.9% during the forecast period.
The immuno-oncology assay demand in South Korea is predicted to flourish at a CAGR of 15.2% through 2034.
In the United States, the immuno-oncology assay industry is estimated to register a CAGR of 12.1% from 2024 to 2034.
The United Kingdom is projected to expand by a CAGR of 13.9% between 2024 and 2034.
The immuno-oncology assay market in Japan is anticipated to record a CAGR of 14.1% during 2034.
“The growing acceptance and utilization of immunotherapy across various cancer types drive the demand for immuno-oncology assays, fueling market growth,” opines Sabyasachi Ghosh, Associate Vice President at Future Market Insights (FMI).

Competitive Landscape
Key players in the sector have fortified their global market positions through the adoption of innovative products and substantial research and development endeavors. As competition intensifies, numerous companies are directing their efforts toward research and the introduction of new diagnostic methodologies, expanding their product lines, and pursuing acquisitions and mergers.

Bio-Rad Laboratories provides a wide range of life science research tools, including instruments, reagents, and assays for genomics, proteomics, and cell biology. Its offerings support various aspects of immuno-oncology assay development and validation.
F. Hoffmann-La Roche Ltd. is a leading provider of diagnostics and pharmaceuticals, offering companion diagnostics for immuno-oncology therapies, as well as research tools and assays for biomarker discovery and validation.
PerkinElmer offers a range of solutions for immuno-oncology research, including imaging systems, high-content screening platforms, and reagents for cellular and molecular analysis.

Comments